Physician profile
Jon Davis
NPI 1053549139
$7,472.70
in general payments reported to CMS, 2019-2025
31 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $776 · 2021: $1,467 · 2022: $1,315 · 2023: $1,426 · 2024: $1,369 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.43 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,031.84 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,036.42 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $740.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $522.63 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $511.02 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $313.88 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $311.65 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $258.50 | 2020-2024 | Dupixent |
| Amgen INC. | $249.00 | 2020-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $215.10 | 2020-2025 | Cabtreo, Jublia |
| Ucb, INC. | $180.27 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $166.85 | 2019-2024 | Adbry |
| Pfizer INC. | $140.21 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $125.19 | 2023-2024 | Zoryve |
| Incyte Corporation | $80.33 | 2022-2023 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $78.00 | 2024 | Filsuvez |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.91 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $62.33 | 2021 | |
| Galderma Laboratories, L.P. | $61.62 | 2024-2025 | Aklief, Nemluvio |
| Krystal Biotech INC | $61.00 | 2025 | Vyjuvek |
| Organogenesis INC. | $54.25 | 2023-2024 | Puraply |
| Dermavant Sciences, INC. | $44.39 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $39.21 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $24.88 | 2025 | Ycanth |
| Prugen, INC. Pharmaceuticals | $20.30 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.57 | 2019 | |
| Biofrontera INC. | $17.54 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Merck Sharp & Dohme LLC | $12.14 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.92 | 2019 | |
| Mission Pharmacal Company | $10.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.